Using advanced synthetic strategies, our team designs and synthesizes complex peptides, delivering tools such as long and difficult peptide sequences, labelled peptides, and small proteins with synthetic or post-translational modifications.
Peptide drug discovery has entered a phase of unusual maturity and momentum, driven by the convergence of advanced display platforms, macrocyclic design, and early developability integration. Together, these capabilities are expanding access to target classes long considered difficult to address…
When a theranostic candidate reaches biodistribution studies, the analytical method is rarely the limiting factor, until it is. Fluorescence has artefacts. Radiolabeling has regulatory overhead. And conventional LC-MS/MS was not built for elemental analysis. The programs that move fastest are…
From target identification and validation to preclinical candidate delivery, IRBM provides the full spectrum of drug discovery capabilities across small molecules, peptides, and antibodies.
Whether you are a biotech or pharma team advancing a novel program end-to-end or seeking specialized expertise to accelerate a critical phase of your pipeline, IRBM operates as a true extension of your research team.
Our factsheet outlines how our integrated, multi-modality approach consistently transforms complex biological challenges into development-ready preclinical assets.
